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Exome Sequencing Identifies Autosomal-Dominant
SRP72 Mutations Associated with Familial Aplasia
and Myelodysplasia
Michael Kirwan,1,2,6,* Amanda J. Walne,1,2,6 Vincent Plagnol,3 Mark Velangi,4 Aloysius Ho,5
Upal Hossain,1,2 Tom Vulliamy,1,2,7 and Inderjeet Dokal1,2,7
Aplastic anemia (AA) and myelodysplasia (MDS) are forms of bone marrow failure that are often part of the same progressive underlying
disorder. While most cases are simplex and idiopathic, some show a clear pattern of inheritance; therefore, elucidating the underlying
genetic cause could lead to a greater understanding of this spectrum of disorders. We used a combination of exome sequencing and SNP
haplotype analysis to identify causative mutations in a family with a history of autosomal-dominant AA/MDS. We identified a hetero-
zygous mutation in SRP72, a component of the signal recognition particle (SRP) that is responsible for the translocation of nascent
membrane-bound and excreted proteins to the endoplasmic reticulum. A subsequent screen revealed another autosomal-dominant
family with an inherited heterozygous SRP72 mutation. Transfection of these sequences into mammalian cells suggested that these
proteins localize incorrectly within the cell. Furthermore, coimmunoprecipitation of epitope-tagged SRP72 indicated that the essential
RNA component of the SRP did not fully associate with one of the SRP72 variants. These results suggest that inherited mutations in
a component of the SRP have a role in the pathophysiology of AA/MDS, identifying a third pathway for developing these disorders
alongside transcription factor and telomerase mutations.Aplasia,oraplastic anemia (AA[MIM609135]), isa condition
in which bone marrow cells fail to produce a sufficient
number of mature cells because of either retarded develop-
ment or a cessation of regeneration. Myelodysplasia, or
myelodysplastic syndrome (MDS [MIM 614286]), is the
description given to a form of bonemarrow failure inwhich
immature cells in the bone marrow become malformed
and dysfunctional.1 These disorders are often part of a
continuum beginning with AA, progressing through MDS,
and in some cases ultimately transforming into acute
myeloid leukemia (AML [MIM 601626]). Most cases of AA
are simplex and idiopathic and MDS is relatively common
in the aged population. However, some cases of AA/MDS
(that is, AA and MDS as part of a disease continuum) are
shown to be familial by presentation in several members of
a family throughmore than one generation and early onset
of disease symptoms. The underlying genetic causes of AA/
MDS are varied, and the genes involved in familial cases
include the hematopoietic transcription factors RUNX1
(MIM 151385)2 andGATA2 (MIM 137295)3 and the telome-
rase components TERC (MIM 602322)4 and TERT (MIM
187270).4 A mutation in the transcription factor CEBPA
(MIM 116897) has also been identified in several cases of
familial AML.5 Many cases, however, remain uncharacter-
ized at the genetic level; hence,we sought toanalyze families
with a history of AA/MDS for inherited mutations.
We initially chose to screen a family (designated family
1) of four individuals affected by bone marrow failure1Barts and The London School of Medicine and Dentistry, Queen Mary, Univ
Hospital, The Royal LondonHospital, London E1 1BB, UK; 3University College
and Laboratory Haematology, Birmingham Children’s Hospital, Birmingham
Singapore 169 608, Singapore
6These authors contributed equally to this work
7These authors contributed equally to this work
*Correspondence: m.j.kirwan@qmul.ac.uk
DOI 10.1016/j.ajhg.2012.03.020. 2012 by The American Society of Human
888 The American Journal of Human Genetics 90, 888–892, May 4, 2and congenital nerve deafness with an apparent auto-
somal-dominant mode of inheritance. The index case
(II-1) was diagnosed with aplastic anemia by bone marrow
biopsy, and two of her siblings (II-2 and II-3) were shown to
be pancytopenic on the basis of full blood counts. One
sibling with normal hearing had normal blood counts
(II-4). The mother (I-2) had myelodysplasia (Figure 1A).
The first analysis performed was a SNP typing approach.
Genomic DNA samples, prepared from peripheral blood
and extracted from all members of family 1 with the
Puregene DNA isolation kit (Gentra, Minneapolis, MN,
USA), were analyzed using the Illumina 6K SNP chip
(service provided by The Genome Centre, Barts and The
London School of Medicine). All samples were obtained
with informed consent and the approval of our local ethics
committee. Analyzing the data with Genehunter6 through
the use of an autosomal-dominant inheritance pattern
over 20 regions within the genome gave a positive
maximum LOD score of 0.9, so this family was not power-
ful enough to give a unique location without large
amounts of follow-up work.
With the advent of whole-exome sequencing, the four
affected members of the family were reevaluated. Approx-
imately 180,000 coding exons from 5 mg of genomic DNA
from each affected individual were captured with the
NimbleGen SeqCap EZ exome library (Roche NimbleGen,
Madison, WI, USA). After cluster generation, the exome
DNA library was then sequenced on the Illumina Genomeersity of London, London E1 2AT, UK; 2Barts and The London Children’s
London Genetics Institute, LondonWC1E 6BT, UK; 4Department of Clinical
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Figure 1. Heterozygous SRP72Mutations Found in Two Families
with Autosomal-Dominant Familial Aplastic Anemia and Myelo-
dysplasia
(A) Pedigrees of the two families. The index case in each family is
indicated by an arrow. Black symbols represent MDS; blue
symbols, AA or pancytopenia. A plus sign indicates a wild-type
allele; a minus sign indicates a mutant allele. The index case
(II-1) in family 1 was found to have pancytopenia (hemoglobin
[Hb] 11.2 g/dl, white blood cell [WBC] count 1.9 3 109/l, neutro-
phils 0.7 3 109/l, platelets 93 3 109/l) when she was admitted for
abdominal pain in 2006 at 14 years of age. The bone marrow
biopsy showed reduced cellularity without significant dysplasia
and normal cytogenetics. The mother (I-2) of the index case was
also found to be pancytopenic, but her BM had features of
dysplasia. Her two younger brothers (II-2, 12 years old and II-3,
11 years old) were also found to be pancytpenic (II-2, Hb
12.3 g/dl, WBC 1.7 3 109/l, neutrophils 0.7 3 109/l, platelets
113 3 109/l; II-3, Hb 12.6 g/dl, WBC 2.1 3 109/l, neutrophils
0.5 3 109/l, platelets 120 3 109/l). The four affected members in
this family have not required any treatment for the hematological
abnormalities. The index case (II-2) in Family 2 was found to have
thrombocytopenia and macrocytic anemia at 33 years of age
(1987). A BM biopsy in 1993 (at 39 years of age) showed her to
have trilineage dysplasia, and the trephine had a cellularity of
40%. The bone marrow karyotype showed no abnormalities. Her
blood count in 2006 (at 52 years of age) showed Hb 12.3 g/dl,
mean corpuscular volume (MCV) 103fl, WBC 4.6 3 109/l, and
platelets 70 x109/l. The index case’s mother (I-2) had been diag-
nosed as having MDS for several years. In 2006 (at 76 years of
age) her blood count was Hb 8.2 g/dl, WBC 4.9 3 109/l, and plate-
lets 22 3 109/l. Both affected cases in family 2 have not had any
specific treatment for the hematological abnormalities.
(B) Example sequence traces showing wild-type (upper) and
mutant (lower) sequences. The left panels show the 2 bp heterozy-
gous CA deletion. The right panels show the heterozygous single-
base G>A substitution.
(C) Schematic showing where the amino acid alterations lie with
regard to prominent domains within SRP72. The nine predicted
TPR protein-protein interaction domains are shown in blue and
The AmAnalyzer IIx (Illumina, San Diego, CA, USA) with the use of
76 base pair (bp) paired-end reads. Sequencing data were
processed through the Illumina pipeline, and unique
heterozygous changes common to all four samples were
identified by filtering the resultant data set against varia-
tions reported on dbSNP and the 1000 Genomes project.
Only coding or splice variants that were present in all
four affected family members were analyzed further, which
left 107 possible variations for analysis (Table S1 available
online). Of these, one was a 2 bp deletion, three introduced
a premature stop codon, and 103 were nonsynonymous
coding single-nucleotide substitutions. The locations of
these mutations were referred back to the SNP data previ-
ously obtained. We excluded any variation that was not
in a region shared by a common haplotype between the
affected individuals. The remaining variations were filtered
through the Exome Variant Server (EVS) to exclude muta-
tions already observed in the population on the assump-
tion that, under an autosomal-dominant mode of inheri-
tance, any change seen should be pathological. Even if
reported at a low incidence on the EVS (e.g., 1 in
10,000), this would still be far higher than the frequency
of AA, which is 2–7 cases per million per year.7 For the re-
maining variations, standard nucleotide sequencing was
performed on the other family members to determine
whether the variant sequences segregated with the disease.
Where a variant was found in an unaffected individual or
absent in an affected individual, this gene was excluded
from further investigation. This left three possible gene
variants of interest: SRP72 (MIM 602122) c.1064_1065del
(p.Thr355Lysfs*19) (NM_006947.3), RAB3GAP1 (MIM
602536) c.1268C>G (p.Pro423Arg) (NM_001172435.1),
and PIWIL3 (MIM 610314) c.2518T>C (p.Tyr840His)
(NM_001008496.3).
Mutations in RAB3GAP1 have previously been associated
withWarburgmicro syndrome (MIM60018), anautosomal-
recessive disorder characterized by microcephaly, micro-
phthalmia, microcornia, congenital cataracts, optic
atrophy, cortical dysplasia, in particular corpus callosum
hypoplasia, severe intellectual disability, spastic diplegia,
and hypogonadism. This gene was therefore excluded,
because thisdisorderhasnophenotypicoverlapwith family
1. Heterozygous individuals are also not reported to display
anydisease phenotype.PIWIL3was excludedon thebasis of
its expressionprofile, giventhat it is expressedexclusively in
the adult testis8 and transmission in both these families is
maternal. This left SRP72 c.1064_1065del (p.Thr355Lysfs*
19) as the only candidate (Figure 1B).
SRP72 is a component of the signal recognition particle
(SRP), which is responsible for arresting translation of
nascent proteins that are destined for the cell membrane
or extracellular secretionand transferring themto the endo-
plasmic reticulum (ER) for correct trafficking. The SRP is
composed of six protein subunits (SRP9 [MIM 600707],numbered; the 7SL RNA binding domain is depicted in red.
Approximate amino acid coordinates are indicated.
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Figure 2. Production of EGPF-SRP72 Fusion Protein in Mammalian Cells
(A) Western blot showing EGFP-SRP72 fusion proteins including wild-type and variant SRP72 sequences. Endogenous SRP72 was
detected with the same antibody but at a much lower level than exogenous protein, requiring a separate, longer exposure time.
Approximate molecular weights (in kDa) are indicated.
(B) HEK293 and rat NRK cells were transfected with the EGFP-SRP72 constructs, and the EGFPwas visualized by fluorescencemicroscopy.
The ER was costained red with ER-Tracker Red. Wild-type SRP72 shows greater coincidence with the ER than either of the variant SRP72
proteins in both cell types, suggesting that the variant SRP72 proteins are not localizing correctly within the cell.SRP14 [MIM 600708], SRP19 [MIM 182175], SRP54
[MIM 604857], SRP68 [MIM 604858], and SRP72) and
a 7SL RNA (MIM 612177).9 The SRP72 c.1064_1065del
mutation is predicted to cause a truncation of the protein,
which effectively deletes the domain that has been
implicated in binding of SRP72 to the 7SL RNA10,11
(Figure 1C), potentially leading to a loss of function. This re-
gion was also initially predicted to be required for binding
SRP68,12 although this has been disputed by a later
study.13
As this was a promising gene candidate, we subsequently
selected an additional 96 individuals with bone marrow
failure for screening of SRP72 (oligonucleotide primers
listed in Table S2), with preference given to those with
a suspected autosomal-dominant mode of disease trans-
mission (n ¼ 35) and/or hearing/ear abnormalities (n ¼
14). These were analyzed by denaturing high-performance
liquid chromatography (Transgenomic, Glasgow, UK) at
a single temperature at which the fragment was at least
80% helical. Any samples that gave abnormal elution
patterns were reamplified and sequenced.
This secondary screen identified one additional indi-
vidual with a heterozygous missense mutation in exon 6
(c.620G>A [p.Arg207His]) (Figure 1B), which was also
not represented on the EVS. Both the index case (II-2)
and the mother (I-2) in this family (family 2, Figure 1A)
presented with MDS, and we were able to confirm that
this mutation was present in both individuals. Interest-
ingly, although no deafness was noted in the family, the
index case presented with possible labyrinthitis, an inflam-
mation of the inner ear. The p.Arg207His substitution
affects an amino acid in the sixth tetratricopeptide repeat
(TPR). The TPRs are predicted to form protein binding sites
that may interact with other proteins of the SRP (such as
SRP54 or SRP68) or ribosomal proteins11 (Figure 1C). In
addition, we screened 120 healthy controls of various
ethnicities and confirmed that neither of these mutations
was prevalent in the general population.890 The American Journal of Human Genetics 90, 888–892, May 4, 2To determine whether these mutations might lead to
a loss of function, we subcloned SRP72 from an expression
plasmid (kindly provided by Prof. Thoru Pederson, Univer-
sity of Massachusetts Medical School14) into plasmid
pEGFP-C1 (Clontech, Saint-Germain-en-Laye, France)
such that it was fused to enhanced green fluorescent
protein (EGFP) at its N terminus. The resultant plasmid
was designated pEGFP-SRP72. The c.1064_1065del
(p.Thr355Lysfs*19) and c.620G>A (p.Arg207His) muta-
tions were introduced by PCR, and the constructs were
resequenced to check sequence integrity. Wild-type and
mutant SRP72 were transfected into human HEK293 and
rat NRK cells with the use of Lipofectamine LTX (Life
Technologies, Paisley, UK), and the ER was costained
with ER-Tracker Red (Life Technologies). Western blotting
with the SRP72 antibody, HPA034621 (Sigma-Aldrich,
Dorset, UK), against transfected HEK293 cell lysates con-
firmed the production of a truncated protein for the
p.Thr355Lysfs*19 variant (Figure 2A). Microscopic obser-
vation of EGFP localization showed that, whereas the
wild-type SRP72 was located mainly in the ER of both
cell types as predicted from previous studies,14 the variant
forms of SRP72 showed reduced colocalization with the ER
(Figure 2B). This diffuse pattern suggests incorrect localiza-
tion, perhaps due to an inability of the SRP72 variants to
bind appropriately to the remainder of the SRP or translo-
cate to the ER. Given that the 7SL RNA binding domain is
absent from the p.Thr355Lysfs*19 variant, we theorized
that this mislocalization might be due to an inability of
the variant proteins to bind to the SRP and its RNA
component.
With the use of the GFP antibody ab1218 (Abcam,
Cambridge, UK) and the Universal Magnetic Co-IP Kit
(Active Motif, La Hulpe, Belgium), the EGFP-SRP72 was
recovered from transfected cells by immunoprecipitation.
Any associated 7SL RNA was isolated with an RNeasy
extraction kit (QIAGEN, Crawley, UK) and reverse
transcribed with SuperScript II reverse transcriptase (Life012
Figure 3. PCR Quantitation of 7SL RNA Coprecipitated from
HEK293 Cells Transfected with Wild-Type and Mutant EGFP-
SRP72 Constructs
(A) Standard PCR of a ~200 bp fragment representing the 7SL RNA
cDNA
(B) Quantitative real-time PCR with a fluorescent primer/probe
assay. Quantitative results are shown as levels relative to those ob-
tained by coprecipitation with the wild-type construct. An EGFP-
only and a mock transfection were included as negative controls,
and a nonimmunoprecipitated HEK293 lysate was included as
a positive control.
(C) Quantitative real-time PCR results normalized to contami-
nating levels of the housekeeping gene ABL1. The result for the
positive control is greatly reduced as a result of the higher levels
of ABL1 in a raw cell lysate compared to one that has been
depleted by coimmunoprecipitation.
Error bars represent SEM from triplicate samples.Technologies) and the 7SL RNA-specific primer 50-GACGG
GGTCTCGCTATGTTG-30. Standard PCR was performed
to amplify a ~200 bp product representing the 7SL RNA
cDNA. This showed a marked reduction in the amount
of 7SL RNA coprecipitated with the p.Thr355Lysfs*19
variant, although this was not apparent with the
p.Arg207His variant (Figure 3A). Quantitative PCR
(qPCR) on an ABI7500 thermal cycler (Life Technologies)
using the TaqMan fluorescent probe (Hs00601540_m1;
Life Technologies) indicated that the level of 7SL RNA
coprecipitated with the p.Thr355Lysfs*19 variant was
around 15% compared to wild-type SRP72 (Figure 3B), as
measured by a nonnormalized qPCR. Although other
mRNA transcripts are largely removed by the immuno-
precipitation process, there was sufficient retention ofThe Amgenomic DNA to allow the use of the housekeeping gene
ABL1 (MIM 189980) (an average Ct value of 26.13, SD
of 0.56) in an attempt to normalize the 7SL RNA reading.
This produced largely the same result (Figure 3C), although
it obviously negatively skewed the result for the positive
control due to the much higher levels of ABL1 in a raw
lysate (average Ct of 20.83, average SD of 0.34). Again,
however, the p.Arg207His variant did not show any lack
of 7SL RNA binding, and in fact demonstrated increased
levels of 7SL RNA coprecipitation, suggesting a different
mode of action for this protein.
Clearly, the p.Arg207His variant should not lack the
SRP68 or SRP RNA binding domains. Given that the amino
acid substitution lies near the middle of the sixth TPR
domain, this change may disrupt binding to SRP68, or
alternatively to SRP54, and thereby destabilize the associa-
tion while still resulting in a similar overall phenotype.
The finding that this variant appeared to coprecipitate
more 7SL RNA is intriguing and might suggest a derange-
ment of particle assembly resulting in a completely aber-
rant stoichiometry.
SRP72 has been implicated in binding to the SRP
receptor and promoting the directional translocation of
newly translated proteins bearing a signal sequence into
the lumen of the ER.15 Failure of SRP72 to either bind to
the complex or interact with the nascent polypeptide
might therefore result in an inability to properly translo-
cate peptides that are otherwise destined for the cell
membrane or extracellular space. Alternatively, although
SRP68 binds weakly to 7SL RNA, the binding of SRP72
significantly enhances this interaction;12 therefore, a lack
of associated SRP72 might destabilize the whole particle,
resulting in a complete failure to arrest cytoplasmic trans-
lation. Precisely how a defect in protein translocation
might result in the AA/MDS phenotype is unclear at this
point, although it is worth noting that genetic defects in
protein processing have been implicated in polycystic liver
disease.16 At face value, such a defect might be expected to
have a global impact on cell membrane and secreted
proteins; however, previous studies of SRP depletion using
interfering RNA have shown that SRP can be massively
reduced (< 10%) without affecting the rate of cell growth
and survival, despite observable defects in protein translo-
cation.17,18 In fact, SRP depletion seems to have very
selective effects. For example, depletion of SRP in cell lines
selectively reduced tumor necrosis factor (TNF)-related
apoptosis-inducing ligand death receptor DR4 and not
DR5, suggesting a specific role in the mediation of
apoptosis via the DR4 pathway.18 Even so, the mutations
identified here are present in the heterozygous state, which
suggests that SRP-dependent protein trafficking, although
perturbed, is unlikely to be completely nonfunctional.
The SRP is already implicated in human disease. In some
cases of polymyositis and dermatomyositis, autoantigens
are generated to the SRP, resulting in chronic inflamma-
tion.19 However, this report identifies human disease
caused by mutation in a component of the SRP. Takenerican Journal of Human Genetics 90, 888–892, May 4, 2012 891
together, these data suggest a role for mutation of SRP72
in familial AA/MDS, adding to the list of genes whose
mutation is known to be linked with these disorders. The
genes previously identified in familial AA/MDS and AML
fall into two functional categories: transcription factors
(RUNX1, CEBPA, and GATA2) and telomere maintenance
(TERC and TERT). The SRP72 mutations reported here
represent a third category: protein translocation and
processing. Further work is therefore warranted to identify
additional mutations, not only in SRP72 but also in other
components of the SRP and the protein-processing
apparatus.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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